These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 20562613)

  • 1. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
    Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
    Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
    D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
    Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
    Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
    J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The safety of perioperative bevacizumab use].
    Mariani P
    J Chir (Paris); 2010 Jan; 147 Suppl 1():S12-7. PubMed ID: 20172200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
    van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
    J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
    Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
    Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
    Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
    Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
    Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
    Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
    Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
    Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
    Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
    J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
    Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J
    Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases.
    Covey AM; Brown KT; Jarnagin WR; Brody LA; Schwartz L; Tuorto S; Sofocleous CT; D'Angelica M; Getrajdman GI; DeMatteo R; Kemeny NE; Fong Y
    Ann Surg; 2008 Mar; 247(3):451-5. PubMed ID: 18376189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
    Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma.
    Rivoire M; De Cian F; Meeus P; Négrier S; Sebban H; Kaemmerlen P
    Cancer; 2002 Dec; 95(11):2283-92. PubMed ID: 12436433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective resection of colorectal liver metastases.
    Tamandl D; Gruenberger B; Herberger B; Schoppmann S; Bodingbauer M; Schindl M; Puhalla H; Fleischmann E; Schima W; Jakesz R; Laengle F; Gruenberger T
    Eur J Surg Oncol; 2007 Mar; 33(2):174-82. PubMed ID: 17046194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portal triad clamping (TC) or hepatic vascular exclusion (VE) for major liver resection after prolonged neoadjuvant chemotherapy? A case-matched study in 60 patients.
    Benoist S; Salabert AS; Penna C; Karoui M; Julié C; Rougier P; Nordlinger B
    Surgery; 2006 Sep; 140(3):396-403. PubMed ID: 16934601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The safety and efficacy of neoadjuvant chemotherapy for patients with hepatic colorectal cancer metastases].
    Miyamoto A; Nakamori S; Tsujie M; Kurokawa Y; Yasui M; Ikenaga M; Miyazaki M; Hirao M; Fujitani K; Mishima H; Tsujinaka T
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2022-4. PubMed ID: 20037311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
    Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.
    Mahfud M; Breitenstein S; El-Badry AM; Puhan M; Rickenbacher A; Samaras P; Pessaux P; Lopez-Ben S; Jaeck D; Figueras J; Alain-Clavien P
    World J Surg; 2010 Jan; 34(1):92-100. PubMed ID: 19838754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.